Gilead's $1.7B hep D drug just ran into a roadblock at the FDA
Gilead was following German biotech Myr and its hepatitis delta virus candidate for “quite some time” before finally pulling the trigger on a $1.7 billion buyout deal. With an EU authorization already under its belt, an OK in the US was all but a done deal — or so it thought.
The company reported an FDA rejection during its Q3 earnings call on Thursday, leaving CMO Merdad Parsey “disappointed” and spoiling the $360 million milestone that Myr would have reaped on an FDA approval. So what happened?
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.